Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
RPGLIFENSERPG Life Sciences Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 15 Dec, 2025 · 15:36 IST

Board approves new WOS for API business, appoints CFO, to invest up to Rs 105 cr

Management Changes View source PDFExplain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.5%Reaction day
₹2371.00
prior close
₹2377.60
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-1.9% vs market
Pharmaceuticals peers, median of 159sector-0.4%-2.1% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
-0.2
15m
-0.4
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.5-0.6-1.9-0.4-2.1
Next day
-1.3-1.5+0.2-1.3-0.0
2d
-2.4-1.8-0.5-1.3-1.1
3d
-1.3-0.6-0.7-0.4-0.9
4d
-1.4+0.8-2.2+0.1-1.5
5d
-0.6+0.8-1.4+0.3-0.8
1w
-0.1-0.2+0.2-0.7+0.6
15d
-0.9+1.1-1.9+0.9-1.7
1m
-2.4-3.5+1.1-2.6+0.1
2m
-17.0-3.2-13.8-4.1-13.0
3m
-18.9-12.8-6.1-10.8-8.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences board approved incorporating a new wholly owned subsidiary, RPG Active Pharma Limited, to house its API business. The company will transfer its API segment (FY25 revenue Rs 90.24 cr, about 13.8 percent of total turnover) to the WOS for about Rs 50 cr, and invest up to Rs 105 cr into it. Separately, Mr. Amol Lone was appointed as CFO and KMP effective December 15, 2025.

Likely market impact

Restructuring to focus the API business under a dedicated subsidiary. Positive for operational clarity, no direct shareholder action needed.